新型碳青霉烯类抗生素多尼培南的药效分析  

Activity analysis of the novel carbapenem-doripenem

作　　者：顾觉奋[1] 王婧[1] 

机构地区：[1]中国药科大学生命科学与技术学院,南京210009

出　　处：《药学与临床研究》2008年第1期37-41,共5页Pharmaceutical and Clinical Research

摘　　要：多尼培南是一种新型的β-内酰胺类抗生素,它具有较广的抗菌谱,与美罗培南相似,对G+菌、G-菌和厌氧菌均具有超广谱强效的抗菌作用。对某些病原体,如铜绿假单胞菌和耐甲氧西林金葡菌,多尼培南比美罗培南有更强效的抗菌活性。多尼培南在美国和欧洲处于Ⅲ期临床研究,用于治疗医院内的严重细菌感染,已获得美国FDA快通道批准治疗院内获得性肺炎,包括呼吸道相关性肺炎。本文就其化学结构、作用机制、抗菌活性、药代动力学及临床应用作一概述。Doripenem was a new member of the carbapenem class of beta-lactam antibiotics with broad-spectrum coverage of Gram-positive, Gram-negative and anaerobic pathogens similar to meropenem. This parenteral antibiotic may offer slightly more activity than meropenem against selected pathogens, including some strains of Pseudomonas aeruginosa. Doripenem was currently in phase Ⅲ clinic in the US and Europe for the treatment of serious bacterial infections in hospital patients. It had also received fast track designation from the FDA for the treatment of hospital acquired （nosocomial） pneumonia, including ventilator-associated pneumonia. The structure, action mechanism, bioactivities, pharmacokinetics and clinical uses of doripenem were overviewed.

关 键 词：碳青霉烯 多尼培南 药效 铜绿假单胞菌 获得性肺炎 

分 类 号：R978.11[医药卫生—药品]